When Dr Andrew Hill, a senior visiting research fellow in the Department of Pharmacology and Therapeutics at the University of Liverpool, discovered that Gilead Sciences had declined to work with the ...

After blasting the U.K.’s drug pricing policy, the pharma industry has secured a new government spending deal featuring a higher revenue cap and an innovative drug-friendly rebate mechanism. In a ...

Rahul Sidhu does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

A "breakthrough" Alzheimer's drug which has been rejected for use on the NHS can slow disease progression by eight years, researchers have revealed. The spending watchdog deemed the benefits of ...